Lung Cancer

1

Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Mazzaschi, G., Minari, R., Zecca, A., Cavazzoni, A., Ferri, V., Mori, C., Squadrilli, A., Bordi, P., Buti, S., Bersanelli, M., Leonetti, A., Cosenza, A, Ferri, L., Rapacchi, E., Missale, G., Petronini

Journal:

Lung Cancer

Year:

2020

File:

PDF, 1.74 MB

2020

2

Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma

Nakashima, Yasuhiro, Inamura, Kentaro, Ninomiya, Hironori, Okumura, Sakae, Mun, Mingyon, Kirimura, Susumu, Kobayashi, Masashi, Okubo, Kenichi, Ishikawa, Yuichi

Journal:

Lung Cancer

Year:

2020

File:

PDF, 4.21 MB

2020

3

Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patient

Kunimasa, Kei, Hirotsu, Yosuke, Miyashita, Yoshihiro, Goto, Taichiro, Amemiya, Kenji, Mochizuki, Hitoshi, Samamoto, Ikuko, Ohki, Takamasa, Oyama, Toshio, Honma, Keiichiro, Imamura, Fumio, Nishino, Kaz

Journal:

Lung Cancer

Year:

2020

File:

PDF, 1.42 MB

2020

4

Baseline Results of the West London lung cancer screening pilot study â Impact of mobile scanners and dual risk model utilisation

Bartlett, Emily C., Kemp, Samuel V., Ridge, Carole A., Desai, Sujal R., Mirsadraee, Saeed, Morjaria, Jaymin B., Shah, Pallav L., Popat, Sanjay, Nicholson, Andrew G., Rice, Alexandra J., Jordan, Simon,

Journal:

Lung Cancer

Year:

2020

File:

PDF, 1.12 MB

2020

5

Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling

Madison, Russell, Schrock, Alexa B., Castellanos, Emily, Gregg, Jeffrey P., Snider, Jeremy, Ali, Siraj M., Miller, Vincent A., Singal, Gaurav, Alexander, Brian M., Venstrom, Jeffrey M., Chung, Jon H.

Journal:

Lung Cancer

Year:

2020

File:

PDF, 2.53 MB

2020

6

Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy

Reck, Martin, Syrigos, Kostas, Miliauskas, Skaidrius, ZÃ¶chbauer-MÃ¼ller, Sabine, Fischer, JÃ¼rgen R., Buchner, Hannes, Kitzing, Thomas, Kaiser, Rolf, Radonjic, Dejan, Kerr, Keith

Journal:

Lung Cancer

Year:

2020

File:

PDF, 1.84 MB

2020

7

Editorial Board

Journal:

Lung Cancer

Year:

2020

File:

PDF, 99 KB

2020

8

PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry

Yoon, Ju-Yoon, Nayyar, Rakesh, Quest, Graeme, Pabedinskas, Dana, Pal, Prodipto, Tsao, Ming-Sound, Schwock, Joerg, Ko, Hyang-Mi

Journal:

Lung Cancer

Year:

2020

File:

PDF, 2.07 MB

2020

10

Targeting polyamine as a novel therapy in xenograft models of malignant pleural mesothelioma

Lam, Sze-Kwan, Yan, Sheng, Xu, Shi, Ho, James Chung-Man

Journal:

Lung Cancer

Year:

2020

File:

PDF, 8.16 MB

2020

11

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers

Yang, Haiyan, Zhou, Zhen, Lin, Li, Yang, Mingxia, Li, Chong, Li, Ziming, Yu, Xinmin, Lizaso, Analyn, Han-Zhang, Han, Li, Bing, Xiang, Jianxing, Mao, Xinru, Xu, Qinqin, Zhang, Yongchang, Yang, Nong

Journal:

Lung Cancer

Year:

2020

File:

PDF, 3.79 MB

2020

12

Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma

Lin, Yi-Tsz, Yang, James Chih-Hsin, Chu, Chia-Yu

Journal:

Lung Cancer

Year:

2020

File:

PDF, 2.37 MB

2020

13

Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis

Ang, Lina, Chan, Cheryl Pui Yi, Yau, Wai-Ping, Seow, Wei Jie

Journal:

Lung Cancer

Year:

2020

File:

PDF, 3.15 MB

2020

14

Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer

Suda, Kenichi, Murakami, Isao, Obata, Keiko, Sakai, Kazuko, Fujino, Toshio, Koga, Takamasa, Ohara, Shuta, Hamada, Akira, Soh, Junichi, Nishio, Kazuto, Mitsudomi, Tetsuya

Journal:

Lung Cancer

Year:

2020

File:

PDF, 1.36 MB

2020

15

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing

Christopoulos, P., Kirchner, M., Roeper, J., Saalfeld, F., Janning, M., Bozorgmehr, F., Magios, N., Kazdal, D., Volckmar, A.L., BrÃ¼ckner, L.M., Bochtler, T., Kriegsmann, M., Endris, V., Penzel, R., K

Journal:

Lung Cancer

Year:

2020

File:

PDF, 2.65 MB

2020

16

Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR

Zhang, Xiangyu, Jiang, Wenjuan, Yang, Nong, Zhang, Yongchang

Journal:

Lung Cancer

Year:

2020

File:

PDF, 832 KB

2020

17

Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation

Wei, Qiang, Zhang, Jin, Chen, Dongsheng, Li, Si, Liu, Yuanhua

Journal:

Lung Cancer

Year:

2020

File:

PDF, 362 KB

2020

18

Novel imprint cytological classification is correlated with tumor spread through air spaces in lung adenocarcinoma

Kimura, Toru, Nakamura, Harumi, Omura, Akiisa, Ike, Akihiro, Hiroshima, Takashi, Maniwa, Tomohiro, Honma, Keiichiro, Higashiyama, Masahiko, Okami, Jiro

Journal:

Lung Cancer

Year:

2020

File:

PDF, 407 KB

2020

19

Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy

Okuma, Yusuke, Ko, Ryo, Shukuya, Takehito, Tateishi, Kazunari, Imai, Hisao, Iwasawa, Shunichiro, Miyauchi, Eisaku, Kojima, Tetsuya, Fujita, Yuka, Hino, Toshihiko, Yamanda, Shinsuke, Suzuki, Toshiro, F

Journal:

Lung Cancer

Year:

2020

File:

PDF, 287 KB

2020

Volume 148

Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma

Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patient

Baseline Results of the West London lung cancer screening pilot study â Impact of mobile scanners and dual risk model utilisation

Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling

Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy

Editorial Board

Contents

PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry

Targeting polyamine as a novel therapy in xenograft models of malignant pleural mesothelioma

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers

Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma

Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis

Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing

Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR

Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation

Novel imprint cytological classification is correlated with tumor spread through air spaces in lung adenocarcinoma

Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy